Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Rituximab maintenance shows no advantage over observation in DLBCL

Pieternella Lugtenburg • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rituximab
HOVON 84 NHL

Pieternella Lugtenburg, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, discusses the results from a randomized Phase III study of rixtuximab maintenance for patients with diffuse large B-cell lymphoma (DLBCL) in first complete remission (HOVON 84 NHL; NTR1014). For this study population, maintenance therapy with rituximab displayed no advantage compared with observation alone. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Pieternella Lugtenburg

2:36
Dutch HOVON lymphoma study group update
Pieternella Lugtenburg • 20 Jun 2019
2:07
Treatment of aggressive NHL in frail patients: cardiac comorbidities and advanced age
Pieternella Lugtenburg • 20 Jun 2019

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals